Unknown

Dataset Information

0

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma.


ABSTRACT:

Background

To explore a more effective treatment strategy for newly diagnosed stage I and II extranodal natural killer/T-cell lymphoma (ENKTL), nasal type, we conducted a prospective phase II study of sequential chemoradiotherapy with the L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) regimen.

Methods

Patients with newly diagnosed stage I and II ENKTL in the upper-aerodigestive tract were enrolled. Treatment was comprised of up to 4 cycles of DICE-L followed by 50 Gy of intensity modulated radiation therapy (IMRT) to the involved field. The primary endpoint was the complete response (CR) rate. The secondary endpoints were the objective response rate (ORR), the 5-year overall survival (OS) rate, the 5-year progression-free survival (PFS) rate, and safety.

Results

A total of 81 patients were enrolled from June 2009 to May 2012 in Shanghai Cancer Hospital. Among these patients, 68 patients achieved CR and 1 patient achieved partial response (PR). The CR rate was 84%, and the ORR was 85.2%. With a median follow up of 88.1 months, the 5-year OS and 5-year PFS rates were 82.4% and 63.4%, respectively. The most common adverse events were grade 3 to 4 neutropenia (73.5%) and febrile neutropenia (21%).

Conclusions

Sequential chemoradiotherapy using DICE-L followed by radiotherapy is an effective treatment modality for stage I to IIE ENKTL and is safe with acceptable toxicity.

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC8350702 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6056977 | biostudies-literature
| S-EPMC5295438 | biostudies-literature
| S-EPMC7738865 | biostudies-literature
| S-EPMC5950589 | biostudies-literature
| S-EPMC5564839 | biostudies-other
| S-EPMC8634181 | biostudies-literature
| S-EPMC5356760 | biostudies-literature
| S-EPMC5530858 | biostudies-other
| S-EPMC4221378 | biostudies-literature
| S-EPMC7073055 | biostudies-literature